RxDoctor Payments Data

Shalin Patel, MD

Interventional Cardiology · Kingston, NYNPI 1164742912

Payments from drug & device makers

$37,932in general payments, 2019–2025

Across 59 payments — averaging $642.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$35K
  • Ancora Heart, Inc.$1K
  • Abbott$848
  • Impulse Dynamics (USA) Inc.$150
  • AstraZeneca$145
  • Medtronic$132
  • plus $279 from 8 others

What the payments were for

  • Travel & lodging$1,27945%
  • Food & beverage$1,54655%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,932 in reported general payments places this provider in the 70th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$297,352
Medicare patients
1,949
Services billed
4,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban364$452,733
EntrestoSacubitril/Valsartan90$134,179
FarxigaDapagliflozin Propanediol58$66,548
XareltoRivaroxaban40$59,721
BrilintaTicagrelor44$44,864
Repatha SureclickEvolocumab18$25,556
Praluent PenAlirocumab28$20,059
Repatha SyringeEvolocumab17$19,351
Metoprolol Succinate277$5,313
Dabigatran EtexilateDabigatran Etexilate Mesylate14$5,259
Atorvastatin Calcium338$4,126
Rosuvastatin Calcium134$2,722
Torsemide101$2,365
Bumetanide50$2,135
Carvedilol198$1,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$452,733364 claims
NovartisEntresto$59$134,17990 claims
AstraZenecaFarxiga, Brilinta$145$111,412102 claims
Johnson & JohnsonXarelto$14$59,72140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →